Skip to main content

Advertisement

Table 2 Potential DAA/ART drug interactions

From: Looking at the positives: proactive management of STIs in people with HIV

DAA ART Change required
DCV EFV Increase DCV dose to 90 mg
DCV NVP/ETR Likely increase DCV dose to 90 mg (no data)
DCV ATZ + EVG/COBI/FTC/TDF Decrease DCV dose to 30 mg
LDV/SOF TDF-based regimens Use with caution, esp. if renal impairment
PROD ART Many drug interactions—do not use
ELB/GRZ PIs Contraindicated—do not use
ELB/GRZ NNRTIs (except RLV) Contraindicated—do not use
ELB/GRZ EVG/COBI/FTC/TDF Contraindicated—do not use
SOF/VEL EFV Contraindicated—do not use
  1. Data source: HepC Drug Interactions (http://www.hep-druginteractions.org)
  2. ATZ atazanavir, COBI cobicistat, DCV daclatasvir, ELB elbasvir, ETR etravirine, EFV efavirenz, EVG elvitegravir, FTC emtricitabine, GRZ grazoprevir, LDV ledipasvir, NNRTIs non-nuclease reverse-transcriptase inhibitors, NVP nevirapine, PIs protease inhibitors, PROD paritaprevir/ritonavir–ombitasvir and dasabuvir, RPV rilpivarine, SOF sofosbuvir, TDF tenofovir disoproxil fumarate